A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Part of paid clinical trials in Lake Forest, California.
- Sponsor
- Amgen
- Study ID
- NCT07590193
- Phase
- PHASE1
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Accepted
Interventions
- AMG 127 — DRUGAMG127 will be administered as either a SC injection or as an IV infusion.
- Placebo — DRUGPlacebo will be administered as either a SC injection or as an IV infusion.
Study Details
The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).
Key Dates
- First listed
- May 15, 2026
- Start date
- Jun 11, 2026
- Status verified
- Jul 2026
- Primary completion
- Oct 2, 2027
- Completion
- Oct 2, 2027
Study Design
- Enrollment
- 162 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Part A: Single Ascending Dose (SAD)Participants will receive single ascending doses of AMG 127 via subcutaneous (SC) injection. One cohort will receive a single dose of AMG 127 as an intravenous (IV) infusion.
- Experimental: Part B: Multiple Ascending Dose (MAD)Participants will receive multiple ascending doses of AMG 127 via SC injection.
- Experimental: Part C: Proof of Mechanism (PoM)Participants will receive multiple doses of AMG 127 via SC injection.
- Placebo Comparator: PlaceboParticipants will receive a matching placebo as either a SC injection or as an IV infusion.
Primary Outcome Measure
Number of Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Part A, SAD: Day 1 to end of trial (up to approximately 58 days); Part B, MAD: Day 1 to end of trial (up to approximately 86 days); Part C, PoM: Day 1 to end of trial (up to approximately 87 days) ]
Central Contacts
- Amgen Call Center866-572-6436
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Orange County Research Center | Lake Forest | California | 92630 | - |
| Translational Clinical Research LLC | Aventura | Florida | 33180 | - |
Find similar trials in Lake Forest, CA
By condition
By specialty
Related Studies
- Use of CGM in Kidney Transplant RecipientsRecruiting · University of California, Davis · Sacramento, California
- DETERMINE: Detemir vs NPHPHASE2 · Recruiting · University of California, Los Angeles · Los Angeles, California
- Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin ResistanceRecruiting · Stanford University · Stanford, California
- Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic PopulationRecruiting · San Diego State University · San Diego, California